Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Daclatasvir, Asunaprevir, and Beclabuvir on SSRI Pharmacokinetics
NCT02175602Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Plasma concentrations of SSRI (escitalopram or sertraline) at 24 hours and Plasma concentrations of DCV, ASV, BMS-791325, and BMS-794712 at 12 hours. Started Jun 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02175602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175602.